Hospital

SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.

The pharmacist integration model filled in gaps in care that appeared to positively affect MIPS and PCMH quality measures.

The antibody drug conjugate was used in combination with the anti-cancer drug SG3249, and demonstrated efficacy in mouse models after 1 week.

Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.

Whitney Lewis, PharmD, BCOP, discusses how the treatment armamentarium for NSCLC has expanded in recent years and the associated cause for this acceleration.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.

Investigators found that older adults, adults with dementia, and adults with altered mental status were more likely to be inappropriately diagnosed with CAP when hospitalized.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

Potential for integration into care and future advancements for gaps in current schizophrenia treatments

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Guidance on evaluating contraceptive options for patients with psychiatric conditions

The finding did not reach statistical significance in the primary composite endpoint.

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.

This is the fifth indication for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo and AstraZeneca) approved by the FDA.

There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.